Literature DB >> 24279313

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

William S M Wold, Karoly Toth1.   

Abstract

Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.

Entities:  

Mesh:

Year:  2013        PMID: 24279313      PMCID: PMC4507798          DOI: 10.2174/1566523213666131125095046

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  112 in total

1.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.

Authors:  Kris Paolino; Jane Sande; Evelio Perez; Brett Loechelt; Barbara Jantausch; Wendy Painter; Margaret Anderson; Tim Tippin; E Randall Lanier; Terry Fry; Roberta L DeBiasi
Journal:  J Clin Virol       Date:  2010-11-19       Impact factor: 3.168

3.  Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response.

Authors:  Anne K Zaiss; Akosua Vilaysane; Matthew J Cotter; Sharon A Clark; H Christopher Meijndert; Pina Colarusso; Robin M Yates; Virginie Petrilli; Jurg Tschopp; Daniel A Muruve
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

4.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.

Authors:  Tony R Reid; Scott Freeman; Leonard Post; Frank McCormick; Daniel Y Sze
Journal:  Cancer Gene Ther       Date:  2005-08       Impact factor: 5.987

6.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

Authors:  Ilkka Liikanen; Laura Ahtiainen; Mari L M Hirvinen; Simona Bramante; Vincenzo Cerullo; Petri Nokisalmi; Otto Hemminki; Iulia Diaconu; Sari Pesonen; Anniina Koski; Lotta Kangasniemi; Saila K Pesonen; Minna Oksanen; Leena Laasonen; Kaarina Partanen; Timo Joensuu; Fang Zhao; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

7.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

8.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Authors:  T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 9.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

10.  Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.

Authors:  Geng Tian; Jiliang Liu; Jie Sui Ruming Zhou; Weihong Chen
Journal:  Anticancer Drugs       Date:  2009-06       Impact factor: 2.248

View more
  171 in total

Review 1.  Viral and cellular interactions during adenovirus DNA replication.

Authors:  Matthew Charman; Christin Herrmann; Matthew D Weitzman
Journal:  FEBS Lett       Date:  2019-12-17       Impact factor: 4.124

Review 2.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

3.  Enzyme/Prodrug Systems for Cancer Gene Therapy.

Authors:  Obeid M Malekshah; Xuguang Chen; Alireza Nomani; Siddik Sarkar; Arash Hatefi
Journal:  Curr Pharmacol Rep       Date:  2016-10-19

4.  Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.

Authors:  Jessica Wingerath; Dmitrij Ostroumov; Norman Woller; Michael P Manns; Daniel D Pinschewer; Klaus Orlinger; Ursula Berka; Florian Kühnel; Thomas C Wirth
Journal:  Mol Ther       Date:  2017-07-20       Impact factor: 11.454

5.  In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration.

Authors:  Megumi Mathison; Vivek P Singh; Maria J Chiuchiolo; Deepthi Sanagasetti; Yun Mao; Vivekkumar B Patel; Jianchang Yang; Stephen M Kaminsky; Ronald G Crystal; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2016-09-23       Impact factor: 5.209

6.  Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients.

Authors:  Xue Yang; Shuangshuang Li; Huiju Wang; Wanyuan Chen; Xiaozhou Mou; Shibing Wang
Journal:  Oncol Lett       Date:  2018-12-24       Impact factor: 2.967

7.  Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.

Authors:  Ekramy E Sayedahmed; Rashmi Kumari; Shruti Shukla; Ahmed O Hassan; Sulma I Mohammed; Ian A York; Shivaprakash Gangappa; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Vaccine       Date:  2018-09-25       Impact factor: 3.641

Review 8.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 9.  Endocytosis in gene therapy with non-viral vectors.

Authors:  Aritz Perez Ruiz de Garibay
Journal:  Wien Med Wochenschr       Date:  2016-05-03

Review 10.  Gene Delivery in Neuro-Oncology.

Authors:  Karan Dixit; Priya Kumthekar
Journal:  Curr Oncol Rep       Date:  2017-09-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.